AzTrials
AzTrials

TuberculosisPhase 1NCT02422524

Pretomanid in Adults With Hepatic Impairment

A Phase 1 study testing PA-824 in people with Tuberculosis, run by National Institute of Allergy and Infectious Diseases (NIAID) at 2 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a Phase 1, single dose (200 mg), open-label study comparing the pharmacokinetics and safety of Pretomanid in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Tuberculosis
What is being tested?
PA-824
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
14 participants
Where
2 sitesUnited States
Study dates
29 Mar 2018to 17 Nov 2023
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Inclusion Criteria for Patients with Hepatic Impairment (Groups 1-3):
  • Subject is able to give voluntary written informed consent before any study related procedure is performed.
  • 18-70 years of age, inclusive.
  • Acceptable laboratory values* obtained at screening (within 21 days prior to admission to the confinement/hospital unit) and either at or within 72 hours of admission to the confinement/hospital unit.
  • Chemistry, complete blood count, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), total bilirubin, alkaline phosphatase, albumin, and urinalysis deemed not clinically significant by the investigator.
  • Hepatic impairment classified as Child-Pugh class A (mild), B (moderate), or C (severe) criteria at screening for Groups 1, 2, or 3, respectively, and documented evidence of hepatic cirrhosis*.
Show all 27Show fewer
  • by biopsy, nuclear scan, CT, MRI, ultrasound, or other clinically acceptable methods
  • If female, not of childbearing potential* or agrees to avoid becoming pregnant by using acceptable contraception** during the duration of the study.
  • Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral oophorectomy or status after hysterectomy.
  • Females of childbearing potential must agree to use two acceptable methods of contraceptives: bilateral tubal ligation; barrier method (condom) by the male partner (even if vasectomized); hormonal contraceptives; intrauterine contraceptive devices; diaphragm in combination with contraceptive jelly, cream, foam, or spermicide; and abstinence from sexual intercourse with men.
  • If subject is male and capable of reproduction, agrees to avoid fathering a child for three months after dosing by using an acceptable method of birth control*.
  • In addition to the use of a barrier method (condom) even if vasectomized, acceptable methods of birth control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #5, and abstinence from sexual intercourse with women.
  • If the subject is female, a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to the confinement/hospital unit.
  • Willingness to comply with all protocol requirements.
  • Inclusion Criteria for Non-Hepatically Impaired Controls (Group 4):
  • Subject is able to give voluntary written informed consent before any study related procedure is performed.
  • 18-70 years of age, inclusive.
  • Subject is a healthy volunteer as determined by no clinically significant findings from medical history, physical examination, vital signs, and 12-lead ECG as determined by the Site Investigator.
  • Acceptable laboratory values* obtained at screening (within 21 days prior to admission to the confinement/hospital unit) and either at or within 72 hours of admission to the confinement/hospital unit.
  • Chemistry, complete blood count, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), total bilirubin, alkaline phosphatase, albumin, and urinalysis within the reference range for the test laboratory, unless deemed not clinically significant by the investigator.
  • If female, not of childbearing potential* or agrees to avoid becoming pregnant by using acceptable contraception** during the duration of the study.
  • Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral oophorectomy or status after hysterectomy.
  • Females of childbearing potential must agree to use two acceptable methods of contraceptives: bilateral tubal ligation; barrier method (condom) by the male partner (even if vasectomized); hormonal contraceptives; intrauterine contraceptive devices; diaphragm in combination with contraceptive jelly, cream, foam, or spermicide; and abstinence from sexual intercourse with men.
  • If subject is male and capable of reproduction, agrees to avoid fathering a child for three months after dosing by using an acceptable method of birth control*.
  • In addition to the use of a barrier method (condom) even if vasectomized, acceptable methods of birth control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #5, and abstinence from sexual intercourse with women.
  • If the subject is female, a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to the confinement/hospital unit.
  • Willingness to comply with all protocol requirements.

Who cannot join

  • Exclusion Criteria for Patients with Hepatic Impairment (Groups 1-3):
  • Hypokalemia (< 3.5mEq/L), severe hypomagnesemia (< 1.1 mg/dL) or severe hypocalcemia (< 7.5 mg/dL).
  • Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 10 times the upper limit of normal.
  • Creatinine clearance < 60 ml/min.
  • Inability to swallow tablets.
  • Presence of any condition or finding* which would jeopardize subject safety, impact study result validity, or diminish the subject's ability to undergo all study procedures and assessments**.
Show all 69Show fewer
  • in the opinion of the site investigator
  • e.g., inability to draw Pharmacokinetics (PK) samples
  • History of fever or documented fever (oral temperature > / = 100.4 degrees F or > / = 38.0 degrees C) in the 48 hours prior to admission to the the confinement/hospital unit.
  • Currently breastfeeding.
  • History of chronic tobacco/nicotine use (> 10 cigarettes per day for 3 months minimum prior to admission).
  • History of clinically significant allergy or severe side effects with nitroimidazoles (e.g., Metronidazole and related substances and azole antifungals or aromatase inhibitors).
  • Receipt of an investigational drug, vaccine or biologic in a clinical trial within 30 days prior to screening.
  • Use of any over the counter (OTC) medication* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
  • including vitamins and herbal supplements, cough and cold medications.
  • in the opinion of the site investigator
  • Treatment with CYP450 enzyme altering drugs* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
  • except hormonal contraceptives
  • in the opinion of the site investigator NOTE: See list of CYP450 enzyme altering drugs under the concomitant medications section.
  • A positive blood screen for HIV.
  • A positive alcohol breath test (or other suitable test for alcohol) or a urine screen test for drugs of abuse* at screening and at admission to the confinement/hospital unit.
  • Amphetamines, barbiturates, cocaine metabolites, marijuana, opiates, phencyclidine (PCP).
  • NOTE: Results of the urine screen test can be ignored if in the opinion of the PI the results can be explained by the concomitant medications history.
  • Unwillingness to abstain from engaging in strenuous physical activity (e.g. running, bicycling, weightlifting, competitive sports) during the course of the study.
  • Consumption of grapefruit juice in the 48 hours before admission to the confinement/hospital unit, or the inability to abstain from these until completion of Day 12.
  • A Heart Rate-Corrected QT Interval (Fridericia's Formula) (QTcF) interval > 450 msec (males) or > 450 msec (females) at screening (Visit 00A) or admission to the confinement/hospital unit (Visit 00B) or a history of prolonged QTc interval.
  • A family history* of Long QT Syndrome, premature cardiac death, or sudden death without a preceding diagnosis of a condition* that could be causative of sudden death.
  • parents
  • due to ischemic heart disease or sudden cardiac death before 55 years of age (men) or 65 years of age (women)
  • such as known coronary artery disease, congestive heart failure, or terminal cancer
  • Any clinically significant ECG abnormality, in the opinion of the site investigator, at screening and at admission to the confinement/hospital unit.
  • Donation of > 500 mL blood within the 30 days prior to admission to the confinement/hospital unit.
  • Plans to donate blood during the study or up to 14 days after dosing.
  • Persons with a transjugular intrahepatic portosystemic shunt.
  • Exclusion Criteria for Non-Hepatically Impaired Controls (Group 4):
  • Inability to swallow tablets.
  • Presence of any condition or finding* which would jeopardize subject safety, impact study result validity, or diminish the subject's ability to undergo all study procedures and assessments**.
  • in the opinion of the site investigator
  • e.g., inability to collect Pharmacokinetics (PK) samples
  • History of fever or documented fever (oral temperature > / = 100.4 degrees F or > / = 38.0 degrees C) in the 48 hours prior to admission to the confinement/hospital unit.
  • Currently breastfeeding.
  • History of chronic tobacco/nicotine use (> 10 cigarettes per day for 3 months minimum prior to admission to the confinement/hospital unit).
  • History of seizures (other than febrile seizures during childhood) or known or suspected Central Nervous System (CNS) disorders that may predispose to seizures.
  • History of clinically significant allergy or severe side effects with nitroimidazoles (e.g., Metronidazole and related substances and azole antifungals or aromatase inhibitors).
  • Receipt of an investigational drug, vaccine or biologic in a clinical trial within 30 days prior to screening.
  • Use of any over the counter (OTC) medication* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
  • including vitamins and herbal supplements, antacids, cough and cold medications.
  • in the opinion of the site investigator
  • Use of prescription medication except hormonal contraceptives within 30 days prior to admission to the confinement/hospital unit, unless* the substance would not likely impact study result validity.
  • in the opinion of the site investigator
  • Treatment with CYP450 enzyme altering drugs* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
  • except hormonal contraceptives
  • in the opinion of the site investigator NOTE: See list of CYP450 enzyme altering drugs under the concomitant medications section.
  • A positive blood screen for HIV.
  • A positive blood screen for hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
  • A positive alcohol breath test (or other suitable test for alcohol) or a urine screen test for drugs of abuse* at screening and at admission to the confinement/hospital unit.
  • Amphetamines, barbiturates, benzodiazepines, cocaine metabolites, marijuana, opiates, phencyclidine (PCP).
  • A history of alcohol abuse or dependence within the past 1 month prior to admission to the confinement/hospital unit.
  • Unwillingness to abstain from engaging in strenuous physical activity (e.g. running, bicycling, weightlifting, competitive sports) during the course of the study.
  • Consumption of grapefruit juice in the 48 hours before admission to the confinement/hospital unit, or the inability to abstain from these until completion of Day 12.
  • A Heart Rate-Corrected QT Interval (Fridericia's Formula) (QTcF) interval > 450 msec (males) or > 450 msec (females) at screening (Visit 00A) or admission to the confinement/hospital unit (Visit 00B) or a history of prolonged QTc interval.
  • A family history* of Long QT Syndrome, premature cardiac death, or sudden death without a preceding diagnosis of a condition* that could be causative of sudden death.
  • parents
  • due to ischemic heart disease or sudden cardiac death before 55 years of age (men) or 65 years of age (women)
  • such as known coronary artery disease, congestive heart failure, or terminal cancer
  • Any clinically significant ECG abnormality, in the opinion of the site investigator, at screening and at admission to the confinement/hospital unit.
  • Donation of > 500 mL of blood within the 30 days prior to admission to the confinement/hospital unit.
  • Plans to donate blood during the study or up to 14 days after dosing.
  • Persons with a transjugular intrahepatic portosystemic shunt.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit

    Durham, North Carolina, 27710-4000

  • Saint Louis University Center for Vaccine Development

    St Louis, Missouri, 63104-1015

Other trials in United States

About this study

Official title: A Phase I, Single Dose, Open-Label Study Comparing the Pharmacokinetics and Safety of Pretomanid in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects

This is a Phase 1, single dose (200 mg), open-label study comparing the pharmacokinetics and safety of Pretomanid in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. There will be approximately 36 total subjects, adult males and females, 18 to 70 years of age, inclusive. The study will be conducted at 2 sites, study duration is approximately 24 months, and subject participation duration is approximately 5 weeks (including screening). Primary objective: To evaluate the pharmacokinetics of a single oral dose of Pretomanid in subjects with mild, moderate, and severe hepatic impairment (as assessed by Child-Pugh score), relative to matched non-hepatically impaired subjects. Secondary objective: To evaluate the safety of a single oral dose of Pretomanid in subjects with mild, moderate, and severe hepatic impairment (as assessed by Child-Pugh score), relative to matched non-hepatically impaired subjects.

Read the detailed description

This is a Phase 1, single dose (200 mg), open-label study comparing the pharmacokinetics and safety of Pretomanid in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. This study will enroll approximately 6 subjects with mild hepatic impairment (Child-Pugh A), approximately 6 subjects with moderate hepatic impairment (Child-Pugh B), approximately 6 subjects with severe hepatic impairment (Child-Pugh C), and approximately 18 matched non-hepatically impaired subjects. Non-hepatically impaired subjects in the control group will be matched to subjects with hepatic impairment based on age (+/- 10 years) and body weight (+/- 20 percent) as measured at screening (Visit 00A). There will be approximately 36 total subjects, adult males and females, 18 to 70 years of age, inclusive. The study will be conducted at 2 sites, study duration is approximately 24 months, and subject participation duration is approximately 5 weeks (including screening). Primary objective: To evaluate the pharmacokinetics of a single oral dose of Pretomanid in subjects with mild, moderate, and severe hepatic impairment (as assessed by Child-Pugh score), relative to matched non-hepatically impaired subjects. Secondary objective: To evaluate the safety of a single oral dose of Pretomanid in subjects with mild, moderate, and severe hepatic impairment (as assessed by Child-Pugh score), relative to matched non-hepatically impaired subjects.

Conditions
Tuberculosis
Being tested
PA-824
Keywords
Hepatic, impairment, PA-824, Pharmacokinetics, Safety, Tuberculosis
Medical subject headings
Tuberculosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PA-824Drug

    Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.

Study groups in NCT02422524
Study groupRoleWhat they receive
Child-Pugh A (Mild hepatic impairment)Experimental6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
Receives: Drug: PA-824
Child-Pugh B (Moderate hepatic impairment)Experimental6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
Receives: Drug: PA-824
Child-Pugh C (Severe hepatic impairment)Experimental6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
Receives: Drug: PA-824
Non-hepatically impaired controlsExperimental18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
Receives: Drug: PA-824

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. AUC(0-infinity): Area Under the Concentration Time-curve Extrapolated to Infinity at Specified Pre-dose and Post-dose Time Points

    AUC(0-infinity) was calculated by noncompartmental analysis using the linear up log down method with the area extrapolated to infinity as Clast/Lambda_z where Clast was the last observed concentration and Lambda_z is the elimination rate constant.

    Measured: Day 1 to Day 5

  2. AUC(0-last): Area Under the Concentration Time-curve to the Last Concentration Above the Lower Limit of Quantitation at Specified Pre-dose and Post-dose Time Points

    AUC(0-last) Area under the concentration time-curve to the last concentration above the lower limit of quantitation at specified pre-dose and post-dose time points was calculated by noncompartmental analysis using the linear up log down method.

    Measured: Day 1 to Day 5

  3. CL/F: Apparent Oral Clearance Calculated From Dose/AUC(0-infinifty) at Specified Pre-dose and Post-dose Time Points

    Apparent oral clearance was calculated by noncompartmental analysis using the formula Dose/AUC(0-infinity).

    Measured: Day 1 to Day 5

  4. Cmax: Maximum Pretomanid Concentration at Specified Pre-dose and Post-dose Time Points

    Maximum Pretomanid concentration is the maximum observed drug concentration in blood plasma at specified pre-dose and post-dose timepoints.

    Measured: Day 1 to Day 5

  5. t(1/2): Apparent Terminal Elimination Half-life at Specified Pre-dose and Post-dose Time Points

    Apparent terminal half-life at specified pre-dose and post-dose timepoints was estimated by ln(2)/Lambda_z, where Lambda_z is the elimination rate constant.

    Measured: Day 1 to Day 5

  6. Tmax: Time of Maximum Pretomanid Concentration at Specified Pre-dose and Post-dose Time Points

    Time of maximum Pretomanid concentration (Tmax) at specified pre-dose and post-dose timepoints.

    Measured: Day 1 to Day 5

  7. Vd/F: Apparent Volume of Distribution at Specified Pre-dose and Post-dose Time Points

    Apparent Volume of Distribution at specified pre-dose and post-dose timepoints is the volume that the total amount of administered drug would occupy to provide the same concentration as it currently is in blood plasma divided by the bioavailability. It is calculated by Dose/[Lambda_z x AUC(0-infinity)]

    Measured: Day 1 to Day 5

Secondary outcomes (6)

  1. Incidence and Severity of Related Adverse Events

    Events were determined to be related if there was a reasonable possibility that the study product caused the adverse event (AE); that is, there was evidence to suggest a causal relationship between the study product and the AE. Each event was graded as mild, moderate or severe. Participants are counted according to their maximum severity of the event reported.

    Measured: Day 1 to Day 12

  2. Incidence and Severity of Serious Adverse Events

    A serious adverse event (SAE) is any adverse event occurring at any dose and regardless of causality that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, is a congenital anomaly or birth defect in an offspring of a subject taking study drug, or is an important medical event.

    Measured: Day 1 to Day 12

  3. Number of Participants With Abnormal ECG Data

    ECG data was collected, including PR interval, QRS duration, QT Interval, QTc interval, RR interval, and Ventricular rate. Abnormal ECG data was evaluated for clinical significance.

    Measured: Day 12

  4. Number of Participants With Abnormal Physical Exam Findings

    Summary of physical examination findings were obtained from a comprehensive physical examination including the following body system assessments: skin; head, eyes, ears, nose, and throat; thyroid; neurological; chest and lungs; cardiovascular; abdomen (liver and spleen); lymph nodes; musculoskeletal, and extremities.

    Measured: Day 3, 4, 5 and 12

  5. Number of Participants With Abnormal Safety Laboratory Parameters

    Summary of abnormal laboratory parameters were collected following dose of study product through day 12. Abnormal findings were evaluated based on relationship to study product and clinical significance.

    Measured: Day 2, 5, and 12

  6. Number of Participants With Abnormal Vital Signs

    Vital signs were collected at each study visit following study product administration. Abnormal vital signs were graded as mild, moderate or severe.

    Measured: Days 1, 2, 3, 4, 5, and 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2015 (estimated)
  2. Study start29 Mar 2018
  3. Primary completion26 Aug 2023
  4. Study completion17 Nov 2023

Why it stopped: The TB hepatic pretomanid PK trial is closed to enrollment. There is no possibility of enrolling and completing the CSR before November 2024.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
14 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02422524
Sponsor's protocol ID
13-0053
Status last verified
14 Dec 2017
First submitted
16 Apr 2015
Last updated
10 Jun 2025
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing PA-824 in people with Tuberculosis, run by National Institute of Allergy and Infectious Diseases (NIAID) at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 69 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 10 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Mar 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

AUC(0-infinity): Area Under the Concentration Time-curve Extrapolated to Infinity at Specified Pre-dose and Post-dose Time Points (time frame: Day 1 to Day 5). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02422524.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in